This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board meeting to approve September 2026 quarterly and half-year results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transchem Limited will hold a Board meeting on November 4, 2026 to approve unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026. Trading by designated persons and their immediate relatives remains closed until 48 hours after the results are made public.
The announcement sets the results date and temporarily restricts insider trading. Shareholder sentiment will depend on the financial numbers and outlook released.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.00 Cr | unchanged |
| Operating profit | −₹1.14 Cr | −₹0.74 Cr | loss widened |
| Profit after tax | ₹2.03 Cr | ₹0.68 Cr | +198.4% |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.